Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00058-6/abstract?utm_campaign=update-laninf&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laninf&_hsenc=p2ANqtz--yRtDOPzBpghPtcJX4C-lMGtbgRGmZtLDwDVeSzeiBk64jJhHvXWF3YM2klbWljPErseJ9jBCKfbnGEytAxpcSwk9ZNw&_hsmi=314129580&utm_content=314072522&utm_source=hs_email